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Background: High-throughput transcriptomics has matured into a very well established and 
widely utilised research tool over the last two decades. Clinical datasets generated on a range 
of different platforms continue to be deposited in public repositories provide an ever-
growing, valuable resource for reanalysis. Cost and tissue availability normally preclude 
processing samples across multiple technologies, making it challenging to directly evaluate 
performance and whether data from different platforms can be reliably compared or 
integrated. 
Methods: This study describes our experiences of nine new and established mRNA profiling 
techniques including Lexogen QuantSeq, Qiagen QiaSeq, BioSpyder TempO-Seq, Ion 
AmpliSeq, Nanostring, Affymetrix Clariom S or U133A, Illumina BeadChip and RNA-seq of 
formalin-fixed paraffin embedded (FFPE) and fresh frozen (FF) sequential patient-matched 
breast tumour samples.  
Results: The number of genes represented and reliability varied between the platforms, but 
overall all methods provided data which were largely comparable. Crucially we found that it 
is possible to integrate data for combined analyses across FFPE/FF and platforms using 
established batch correction methods as required to increase cohort sizes. However, some 
platforms appear to be better suited to FFPE samples, particularly archival material.  
Conclusions: Overall, we illustrate that technology selection is a balance between required 
resolution, sample quality, availability and cost. 
 
 






































































Since their inception microarrays have been adopted as a major tool for the study of clinical 
samples to improve our understanding of diseases, development of molecular subtyping and 
prognostic signatures for clinical decision-making (1). A crucial consideration for many clinical 
studies is whether new data generated can be directly compared or integrated with pre-
existing datasets for robust classification and response prediction. 
RNA sequencing (RNAseq) has somewhat supplanted microarrays for transcriptome analysis. 
However, in translational research when the focus is often restricted to identifying 
differentially expressed genes and pathways, rather than detecting specific isoforms and 
splice variants, decisions on which platform to use are often based upon cost, rather than 
resolution, particularly if this means more samples can be examined to maximise statistical 
power for a fixed budget. Indeed, RNAseq is not without its limitations, Robert and Watson 
recently demonstrated that RNAseq is unable to accurately measure expression of hundreds 
of genes in the human genome (2).  
Many high-throughput profiling studies rely on sample availability and cost rather than 
statistical power (1). Direct integration of datasets enables meta-analysis and has the 
potential to improve statistical power and the generalisability of results for robust 
classification and response prediction. However, non-trivial systematic bias or ‘batch effects’ 
can occur within and between microarray platforms (3–6). Contrary to The MicroArray Quality 
Control guidelines (7), gene expression data can be directly integrated and robust results can 
be produced from fundamentally different technologies such as Affymetrix GeneChips and 
Illumina BeadChips (3). This finding has since been supported by other studies (8, 9).  
Early microarray studies involving clinical samples were dependent on relatively large 
amounts of high quality RNA and thus relied heavily on the availability of fresh frozen (FF) 
tissue. However, collection and storage of FF tissue is costly and can be logistically prohibitive. 
Protocols and technologies capable of generating high quality whole-genome transcriptomic 
data from archival formalin fixed paraffin embedded (FFPE) tissues are in demand (10). FFPE 
tissues are available routinely in the clinical setting and can be stored at ambient temperature 
for many years, allowing easy transportation. A large number of studies have compared 
matched FF and FFPE samples, with some reporting reduced efficacy or numbers of detected 
transcripts and batch effects similar to those reported for different profiling technologies 
(recently reviewed (11)). Most studies conclude that the data can be compared to some 
extent, subject to certain considerations, accepting that RNA from FFPE samples is often 
degraded and continues to degrade with age (10). Whilst earlier microarray technologies 
performed poorly with degraded RNA, newer kits and platforms have emerged using targeted 
sequencing such as Ion AmpliSeq Transcriptome and BioSpyder TempO-Seq or 3’ sequencing 
from Lexogen QuantSeq. Other technologies such as NanoString are promising, but are 
limited to panels of genes rather than whole genome transcriptome. In this study, a number 





































































All patients gave informed consent and the study was approved by the local ethics committee 
(LREC; 2001/8/80 and 2001/8/81). RNA was extracted from primary human breast cancer 
samples collected over 15 years at the Edinburgh Breast Unit from post-menopausal women 
with estrogen receptor positive disease, treated with 3-months of neoadjuvant endocrine 
therapy. Sequential biopsies were taken pre-treatment, early (14-days) on-treatment and at 
surgery 3-6 months later (late on-treatment) from each patient. Part of the biopsy material 
collected was snap-frozen in liquid nitrogen and part was fixed in formalin and embedded in 
paraffin. RNA was extracted from fresh frozen tissue using the Qiagen miRNeasy kit and from 
2x20µm FFPE tissue sections using the RNeasy FFPE kit using the manufacturer’s standard 
protocols for each kit. Agilent RIN values for fresh frozen tissue were >7 and for FFPE tissue 
were <3.  
Transcriptomics 
Building upon large scale clinical studies to investigate the effects of endocrine therapy on 
breast cancer using Affymetrix U133A arrays (12) and Illumina HT12-V4 BeadChips (13), this 
study, utilised patient-matched sets of samples across a range of transcriptomic technologies: 
Affymetrix Clariom S, NanoString, Ion AmpliSeq Transcriptome, BioSpyder TempO-seq (14) 
Lexogen QuantSeq and RNA-seq (Table 1). Microarray samples were processed as directed by 
the manufacturer’s instructions. Nanostring profiling was performed using nCounter 
technology as per the manufacturer’s instructions. Sequencing was performed as described: 
Ion Ampliseq samples were processed using an Ion a PI™ Chip Kit v3 and sequenced using an 
Ion Proton™ System. QiaSeq samples were sequenced using the NextSeq 500/550 High-
Output v2 (150 cycle) Kit on the NextSeq 550 platform. For TempoSeq samples, single read 
(1x75bp) sequencing was performed using the NextSeq 500/550 High-Output v2 (75 cycle) Kit 
on the NextSeq 550 platform. For QuantSeq samples were either processed via single read 
(1x75bp) sequencing performed using the NextSeq 500/550 High-Output v2 (75 cycle) Kit on 
the NextSeq 550 platform or via Ion a PI™ Chip Kit v3 and sequenced using an Ion Proton™ 
System. For RNASeq samples the TruSeq Stranded Total RNA Library Prep Kit with Ribo-Zero 
Gold (Illumina) was used and sequencing was performed on an Illumina HiSeq 2500 using a 
2x50bp configuration with an average of 136 million read pairs per sample. All data is publicly 
available from NCBI GEO (www.ncbi.nlm.nih.gov/geo/) under super-series accession 
GSE130645. 
Data Analysis 
Illumina and Affymetrix data were pre-processed and normalised as described previously (3). 
NanoString data were generated using the nSolver 3.0 software. Ion AmpliSeq Transcriptome 
data were generated using the AmpliSeq RNA plugin in the Torrent Suite Software and 
normalised using RPM (reads assigned per million mapped reads) method. QiaSeq FASTQ files 
were uploaded to the GeneGlobe Data Analysis Center, an online platform provided by 
QIAGEN. The primary analysis module for the UPX 3’ Transcriptome Kit was used to generate 


































































.bcl format was transferred from the NextSeq instrument to a Linux system, where 
demultiplexed FASTQ files were generated using Bcl2fastq2 v2.17.1.14 software provided by 
Illumina. The lane-splitting feature was disabled to create a single FASTQ file for each library. 
FASTQ files were then uploaded to the BlueBee genomics platform 
(https://www.bluebee.com) and read-trimming and alignment was performed using the 
QuantSeq plugin. TempoSeq FASTQ files were sent to BioCalvis (the manufacturer of 
BioSpyder), who performed the alignment and then generated the raw (un-normalised) gene 
counts file using their proprietary software. For RNAseq, alignment was performed using 
STAR74. Transcript abundance estimates for each sample were performed using Salmon, an 
expectation-maximization algorithm using the UCSC gene definitions. Raw read counts for all 
RNAseq samples were normalized to a fixed upper quartile.  
All sequence data were aligned to the human reference hg19 genome. For all data, probes or 
genes were then mapped to Ensembl gene annotations: Affymetrix datasets were mapped 
using a chip definition file (CDF) (15) and all other datasets were mapped using BioMart. All 
data were Log2 transformed and filtered for those expressed in 70% of samples using the 
cluster 3.0 software then quantile normalised using the R/Bioconductor software and 
packages (16). Following data integration, correction of systematic bias was performed using 
ComBat as described previously (3).  
 
Results 
Performance and cost comparison of platforms for FF and FFPE tissue 
Each of the nine technologies evaluated here have different mRNA input requirements, probe 
designs (Fig. 1A) and protocols (summarised in Table 1). Although the total number and 
position of probes/primers/counts varies widely among the transcriptome-wide approaches 
(Table1, Fig. 1A), a common set of 7365 Ensembl transcripts were represented across the six 
whole transcriptome platforms (Fig. 1B). Nanostring and Affymetrix U133 were omitted as 
they do not represent the whole transcriptome and the Clariom S was excluded as only three 
samples were processed). RNAseq may have the highest resolution, but also the highest RNA 
input requirement (100-4000ng) and it is the most expensive whole transcriptome technology 
at two to five times the cost of other approaches (Table 1). The NanoString platform could be 
cost-effective for a small number of genes, but compares poorly on price for large numbers 
of genes (costed for maximum coverage in a single experiment: 770 genes). The newest and 
least expensive technologies are Affymetrix Clariom S array with WT Pico kit and Lexogen 
QuantSeq. Success rate is an important consideration for clinical studies, particularly with 
before and on-treatment matched samples considered in this study. Looking at the numbers 
of samples which have failed using different technologies based on the respective 
manufacturers quality control criteria we found that success rates for generating robust 
expression profiles from FFPE tissues were excellent (>95%) for the latest Lexogen QuantSeq, 
Qiagen Qiaseq, BioSpyder TempO-Seq methods. This is despite the RNA integrity number 
(RIN) values for fresh frozen tissue normally being above 7, but for FFPE tissues were generally 
less than 3. However, success rate was moderate for the Ampliseq RNA Transcriptome (83%) 


































































success rate (91-100%) with several hundred samples processed on the Illumina BeadChip, 
Affymetrix U133A chips and RNAseq (Table 1). As shown previously (10), older FFPE samples 
were found to perform very poorly with the more established technologies (Fig. 1C) whereas 
NanoString, Lexogen QuantSeq and RNA-seq were found to work well with old FFPE tissue-
derived RNA. 
 
Integration of datasets across platforms while preserving biological variability  
To evaluate how newer technologies with desirable features such as lower costs or RNA input 
requirements compared to the more established methodologies, we profiled the same RNA 
from a subset of samples to directly compare gene expression measurements across the 
platforms (Supplementary Table 1). These comparisons have two purposes; firstly to 
determine whether the new technology provides similar quality results to the established 
method. Secondly, to evaluate whether it will be possible to directly integrate datasets 
generated on the new platform with existing local or publicly available data from another 
platform, as we have done previously (3, 4, 6). Indeed, while it is altruistic to minimise 
measurement error by using the same platforms, with constantly evolving technologies and 
lower associated costs this is not often realistic. Therefore, the ability to implement 
approaches to increase validity across platforms is of great importance.  
Not surprisingly, when all samples were integrated together low correlations (r=0.4-0.6) were 
observed between pairs of samples processed on different technologies. Hierarchical 
clustering showed clearly that gene expression values group by technology and technical 
artefacts, rather than by genuine biology (Fig. 2A, left). Following batch correction using the 
well-established and highly cited ComBat method (17), correlations were much higher and 
the majority of ‘paired’ samples clustered together, indicating greater variation between 
biological samples than between gene expression measurement platforms (Fig. 2A, right). 
Looking more closely, instances of the same time-point processed on different platforms 
clustered closely (if not together) and different time points from the same patients showed 
variation (due to treatment), whilst also often clustering with other time points from the same 
patient (Fig. 2B), as has been previously shown for sequential patient-matched samples (13). 
These results are consistent with our previous results showing a reduction in technical 
artifacts, without loss of biological variation (3). 
Clear batch effects were evident when comparing mRNA extracted from FF samples across 
Illumina HT12, Ion Ampliseq Transcriptome and Affymetrix Clariom S, with low Pearson 
correlations (r=0.4-0.58). However standard batch correction approaches such as ComBat 
(17) minimised technical bias effect and increased correlation to r>0.9 for paired samples. 
Similar low correlations and improved correlations following batch correction were observed 
for different technologies with FFPE samples and for comparisons of matched FF and FFPE or 
for the same sample across different platforms (Fig. 2C). Comparison of measurements of the 
56 overlapping genes assayed using NanoString, whole-genome (Illumina HT12) and part-
genome (Affymetrix U133A) expression microarrays were also significantly improved 


































































Looking at the samples more closely by multi-dimensional scaling it is clear that whilst they 
cluster by platform before batch correction (Fig 3A), afterwards they do not (Fig 3B) and more 
importantly, instead they cluster by time point (Fig. 3C). Pre-treatment samples are most 
clearly separated from late on-treatment samples, with early on treatment samples in-
between, as would be expected.  
For further confirmation of the validity of the batch-corrected data, we ranked samples by 
expression of 42 proliferation genes, previously reported by us [12] that change with 
endocrine therapy (list of gene provided in Supplementary Table 2). Molecular changes in the 
tumours reflect the ultrasound measurements across the eleven breast tumours, concordant 
with consistent reductions in tumour volume over time across the patients (Fig. 3C). Ranked 
by proliferation genes the samples are ordered by time point, consistent with our previous 
results [12], and not by platform or preservation method (Fig. 3B). These results suggest that 
comparable gene expression profiles can be generated across the platforms using FFPE 
material and FFPE is a reliable alternative to FF (Fig. 3D). 
Discussion 
Overall we find that gene expression data from the newer technologies is largely concordant 
with that from the more established methods. The newer 3' sequencing approaches from 
Lexogen and Qiagen appear highly reliable and cost effective for old FFPE samples, this 
potentially allows valuable data to be generated from clinical samples that would not have 
been previously possible. The TempO-Seq method (14) from BioSpyder is an interesting 
approach as you can analyse expression without pre-amplification directly from a micro-
dissected area of interest taken from a single FFPE section, maximizing utilization of precious 
or limited samples. Full RNAseq analysis is often considered the gold standard, however when 
tissue samples are particularly small or there is a desire to perform a range of assays or multi-
omic approaches, the newer targeted sequencing approaches with many fold smaller input 
requirements may be a much more attractive proposition. A number of previous studies have 
conducted comparisons of the same samples generated from fresh and archived tissues (18, 
19). The numbers of detected genes from FFPE samples has previously been shown to be 
lower than from fresh tissue (19), however protocols have continued to improve (10). It is 
important to remember that in all pairwise tissue comparisons where RNA is extracted 
separately that they cannot represent exactly the same material and are only ever adjacent, 
leading to inevitable potential minor variations in tissue composition. Despite this, the well-
established Combat method for batch correction (17) was again found to perform well to 
integrate data from different sample types or technologies, this approach has been found to 
be superior in a many of previous studies (20).      
A general finding of most platform comparison approaches is that although the correlation 
values between different microarray or sequencing approaches may be poor to moderate, 
which may relate to differences in dynamic range of the technologies, there is generally very 
high concordance when considering differentially expressed genes (3, 6, 21). A 
comprehensive study of TCGA data found only 1.2 % of genes were inconsistent by fold 
change (21). A wider issue with transcriptomic studies that there is no optimal analysis 


































































This single study perhaps considers the widest range of gene expression technologies using 
FF and FFPE tissues published to date, but we acknowledge that this study documents a 
translational research group’s experiences, rather than being a definitive, comparison study. 
Not every sample was tested on every platform and some leading technologies remain to be 
tested, including Agilent, TaqMan and Fluidigm - due to local availability and opportunities. 
 
Conclusion 
This study highlights the relative merits and limitations of a range of new and established 
gene expression profiling platforms and demonstrates that transcriptomic data from FFPE 
archival samples can be reliably integrated with data from FF samples, even if different 
measurement platforms are used. Ultimately, the choice of technology will depend upon the 
required resolution and coverage, throughput, sample quality, availability and budget. 
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Fig. 1: Comparison of gene expression profiling approaches (A) Schematic of probe/primer 
designs for each technology. A table showing which samples were processed on each 
technology is provided in supplementary Table 1. (B) Number of overlapping Ensembl gene 
identifiers detected in each dataset (Nanostring and Affymetix U133 were omitted as they do 
not represent the whole transcriptome and the Clariom S was excluded as only three samples 
were processed). (C) Summary of FFPE sample processing success rates by sample age using 
whole-transcriptome platforms. 
Fig. 2: Batch correction allows robust direct integration of transcriptomic data across 
platforms. (A) Dissimilarity heatmaps based upon Pearson correlations ranging from 0.4 (red) 
through shades of orange and yellow to 1.0 (white). Left triangle shows the combined dataset 
of 6844 genes across 7 gene expression platforms. Right triangle shows the same data 
following batch correction with Combat. Coloured bars below dendrograms denote the 
platform. (B) Enlargement of the dendrogram to demonstrate that the majority of the same 
time-point patient samples processed on different platforms cluster together following batch 
correction. (C) Scatter plots before (grey) and after batch correction (pink) of the same 
sample, either FF or FFPE processed across different platforms. In each case the Pearson 
correlations increase substantially following batch correction. Patient samples are denoted -
1 for pre-treatment, -2 for early on-treatment. 
Fig. 3: Robust gene expression measurement across platforms following batch correction. 
Correction of systematic platform bias and integration of data from fresh frozen and FFPE 
tissues. (A) 3D multi-dimensional scaling (MDS) before (left) and after (right) batch correction 
of 6844 common genes. Samples coloured by platform and shapes indicates time point. (B) 
MDS plot of the batch corrected data with samples coloured by time-point clearly 
demonstrates a consistent treatment effect seen across sequential patient-matched samples. 
(C) Ultrasound measurements of the eleven breast tumours which relate to the sequential 
patient-matched samples indicating consistent reductions in tumour volume over time across 
the patients. (D) Ranking patient samples by the expression of 42 common proliferation genes 
(listed in Supplementary Table 2) illustrates consistent changes resulting from endocrine 
therapy, which appears to be independent from profiling platform. Pre-treatment samples 
tend to have relatively high proliferation, whilst as expected early, and particularly late on-
treatment samples have lower proliferation. Heatmap colours are Red=High, Green=low.    
 
Additional Files 
Additional file 1 – Supplementary Table 1 
Table demonstrating the directly overlapping samples across the nine gene expression 
platforms coloured by sample type, Pink=FFPE, yellow=fresh frozen. 
Additional file 2 – Supplementary Table 2 


































































Table 1. Comparison of traditional and new microarray platforms with sequencing approaches  
*Input RNA reflects quantities used in this study – for input ranges refer to the manufacturer’s guidelines. 
**Estimated costs (£, UK December 2019) include library preparation and sequencing. Costs can vary by sample numbers and sequencing 
infrastructure. 




























RNA → RT, oligodT priming from 3’ end, 
random priming towards 3’ end → 
amplification and barcoding → sequencing 
96 samples 
per 5 days  
 
55,765 25,610 10M 500 90 N/A 98% (318) 
QiaSeq UPX 3’ 
Transcriptome 
RNA → RT, oligodT priming for cDNA 
synthesis →template switching for 2nd 
strand synthesis priming → fragmentation 
→ end repair addition, adapter ligation → 
PCR to add indices → sequencing 
96 samples 
per 5 days 






RNA → annealed 50bp detector oligos are 
ligated then amplified and barcoded → 
sequencing 
192 samples 
per 4 days  19,300 19,300 12M 
20µm FFPE 
Section 
160 N/A 95% (38) 
Ion Ampliseq 
Transcriptome 
RNA → RT, multiplex PCR → sequence 
barcoding → emulsion PCR → sequencing 
of ~150bp targets 
96 samples 
per 5 days  
 




RNA → hybridisation to fluorescent 
barcoded probes in solution → 




800 800 N/A 50 250 N/A 100% (12) 
Newer 
Microarray 
Affymetrix Clariom S RNA → cRNA  amplification  → 
hybridisation to GeneChip →  scan 
192 samples 
per 4 days  
211,300 >20,000 N/A 50 100 100% (3) 100% (8) 
Traditional 
Microarray 
Affymetrix  U133A 192 per day 250,833 11,827 N/A 50 360 100% (178) 100% (286) 
Illumina BeadChip  
HT-12 v3 / v4 
RNA →RT, amplification,  biotinylation 
(NuGEN WT Ovation kit) → hybridisation to 
50bp probes on chip → scan 
96 samples 
per 1.5 days 
 




RNA → fragmentation → RT → barcoded 
library construction → genome-wide full 
RNA sequencing 
8 samples 






































































































Uncorrected Data After Combat Correction
  
Supplementary Table 1
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